5 completed, 3 recruiting, 3 terminated, 1 active not recruiting. 12 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 5, Recruiting 3, Terminated 3, Active not recruiting 1 |
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
Follow Pleural Mesothelioma: new trials by email Literature Review of Pleural Mesothelioma trials Research Report on Pleural Mesothelioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| A Study of MT027 in Patients with Pleural Malignant Tumors MT027 cells suspension - Advanced Malignant Solid Tumor, Malignant Pleural Effusion | Phase 1 | Recruiting | Suzhou Maximum Bio-tech Co., Ltd. | 18 | 2024-05-15 | 2024-12-10 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S QBS10072S - Astrocytoma, Brain Cancer | Phase 1 | Completed | Quadriga Biosciences, Inc. | 15 | 2020-07-20 | 2023-01-18 |
| A Study of SGN-CD228A in Advanced Solid Tumors SGN-CD228A - Cutaneous Melanoma, Pleural Mesothelioma | Phase 1 | Terminated | Seagen Inc. | 88 | 2019-09-03 | 2023-03-23 |
| Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma Galinpepimut-S, Nivolumab, Sargramostim - Mesothelioma, Pleural Mesothelioma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2019-07-24 | 2025-05-13 |
| A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma Pembrolizumab, Cisplatin and Pemetrexed - Pleural Mesothelioma | Phase 1 | Terminated | University of Chicago | 7 | 2016-02-25 | 2024-07-31 |
| TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs) - Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 9 | 2015-05-15 | 2023-01-10 |
| Gene Therapy for Pleural Malignancies Adenoviral-mediated Interferon-beta, SCH 721015 - Pleural Mesothelioma, Metastatic Pleural Effusions | Phase 1 | Completed | University of Pennsylvania | 17 | 2006-03-01 | 2020-03-18 |
| Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma Cisplatin, Sodium Thiosulfate - Pleural Mesothelioma, Malignant Pleural Mesothelioma | Phase 1 | Completed | Dana-Farber Cancer Institute | 70 | 1999-08-01 | 2014-03-27 |
Mesothelioma, Malignant (12) · Neoplasm Metastasis (6) · Melanoma (5) · Colorectal Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Esophageal Neoplasms (3) · Neoplasms (3) · Stomach Neoplasms (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Transitional Cell (2) · Endometrial Neoplasms (2) · Kidney Neoplasms (2) · Liver Neoplasms (2) · Mesothelioma (2)
Adenoma (12) · Lung Diseases (12) · Neoplasms by Histologic Type (12) · Neoplasms by Site (12) · Neoplasms, Glandular and Epithelial (12) · Neoplasms, Mesothelial (12) · Pleural Neoplasms (12) · Respiratory Tract Diseases (12) · Respiratory Tract Neoplasms (12) · Thoracic Neoplasms (12) · Lung Neoplasms (11) · Mesothelioma (10) · Neoplasms (9) · Digestive System Diseases (6) · Digestive System Neoplasms (6)
pembrolizumab (3) · Cisplatin (2) · Interleukin-2 (2) · Nivolumab (2) · Cyclophosphamide (1) · Docetaxel (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Ipilimumab (1) · Leucovorin (1) · Levoleucovorin (1) · Pemetrexed (1) · aldesleukin (1) · fludarabine (1) · fludarabine phosphate (1) · sargramostim (1)
7 Hills Pharma, LLC (1) · Dana-Farber Cancer Institute (1) · IDEAYA Biosciences (1) · Medicenna Therapeutics, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · NuCana plc (1) · Quadriga Biosciences, Inc. (1) · Seagen Inc. (1) · Suzhou Maximum Bio-tech Co., Ltd. (1) · University Health Network, Toronto (1) · University of Chicago (1) · University of Pennsylvania (1)
United States (8) · Australia (2) · Canada (2) · Spain (2) · United Kingdom (2) · China (1) · France (1) · Ireland (1) · Italy (1) · Portugal (1) · South Korea (1) · Switzerland (1)
Anu Gupta, MD (1) · Arash Yavari, MBBS (1) · Daniel H. Sterman, M.D. (1) · David J. Sugarbaker, MD (1) · Edward Chan, MD (1) · Hedy Kindler, MD (1) · Lionel Lewis, MA, MB.Bch, MD (1) · Marcus Butler, M.D. (1) · Michael Offin, MD (1) · Nina Merchant (1)
2023 (1), P01CA066726 (1)